Item 5.07 Submission of Matters to a Vote of Security Holders

At the Annual Meeting of the Stockholders of Nektar Therapeutics, a Delaware corporation (the "Company"), held on June 10, 2021 (the "Annual Meeting"), the following actions were taken. The proposals below are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2021.





Proposal 1

Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2024 Annual Meeting of Stockholders.





Nominee                For        Against     Abstain   Broker Non-Votes
Jeff Ajer          154,825,666   2,011,006    118,643      12,620,716
Robert B. Chess    154,773,452   2,067,747    114,116      12,620,716
Roy A. Whitfield   112,205,176   44,631,969   118,170      12,620,716

In addition to the directors elected above, Myriam J. Curet, Karin Eastham, R. Scott Greer, and Howard W. Robin, continue to serve as directors after the Annual Meeting.





Proposal 2

The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 5,000,000 shares was approved with approximately 86% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 14% voting against the proposal.





    For        Against     Abstain   Broker Non-Votes
135,391,543   21,456,660   107,112      12,620,716




Proposal 3

The proposal to ratify the appointment, by the audit committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021 was approved with approximately 99% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 1% voting against the proposal.





    For        Against    Abstain   Broker Non-Votes
168,008,555   1,453,373   114,103          0




Proposal 4

The proposal to approve the compensation of the Company's Named Executive Officers, on a non-binding advisory basis, was approved with approximately 97% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 3% voting against the proposal.

For Against Abstain Broker Non-Votes 151,749,699 5,030,154 175,462 12,620,716

© Edgar Online, source Glimpses